PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	Substitute for form 1449/PTO			Complete if Known		
		-		Application Number	10/567,630-Conf. #2853	
IN	FORMATIC	ON DIS	CLOSURE	Filing Date	February 8, 2006	
S	TATEMENT	BY AF	PPLICANT	First Named Inventor	Kari Alitalo	
				Art Unit	Norvet Assigned 1634	
	(Use as many sheets as necessary)			Examiner Name	Kapushoc	
Sheet	1	of	2	Attorney Docket Number	28113/39467A	

U.S. PATENT DOCUMENTS							
Examiner	Cita	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	Cite No.1	Number-Kind Code <sup>2</sup> ( if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
	A1	US-4,946,778	08-07-1990	Ladner et al.			
	A2	US-5,093,246	03-03-1992	Cech et al.			
	A3	US-5,116,742	05-26-1992	Cech et al.			
	A4	US-5,225,337	07-06-1993	Robertson et al.			
	A5	US-5,254,678	10-19-1993	Haseloff et al.			
	A6	US-5,939,598	08-17-1999	Kucherlapati et al.			

		FOREI	GN PATENT	DOCUMENTS		
Everniner	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO 00/32765	06-08-2000	Immusol, Inc.		
	B2	WO 90/07641	07-12-1990	Sundstrand Corporation		
	ВЗ	WO 93/23569	11-25-1993	Ribozyme Pharmaceuticals, Inc.	:	
	B4	WO 94/02602	02-03-1994	Cell Genesys, Inc.		
	B5	WO 96/33735	10-31-1996	Cell Genesys, Inc.		
	B6	WO 96/34096	10-31-1996	Cell Genesys, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	C1	Artavanis-Tsakonas, Science, Vol. 284, pp.770-776 (1999).	L				
	C2	Bach et al., Carcinogenesis, Vol. 21, pp.469-476 (2000).					
	C3	Bange et al., Cancer Res., Vol. 62, pp.840-847 (2002).	L.,				
	C4	Brummelkamp et al., Science, Vol. 296, pp.550-553 (2002).					
	C5	Cavallaro et al., Nat. Cell Biol., Vol. 3, pp.650-657 (2001).					
	C6	Chowrira et al., Nucleic Acids Res., Vol. 20, pp.2835-2840 (1992).					
	C7	Cote et al., Proc. Natl. Acad. Sci. (USA), Vol. 80, pp.2026-2030 (1983).					
	C8	Daubendiek et al., Nat. Biotechnol., Vol. 15, No. 3, pp.273-277 (1997).					
	C9	Elbashir et al., <i>Genes Dev.</i> , Vol. 15, pp.188-200 (2001).	<u> </u>				
	C10	Elbashir et al., Nature, Vol. 411, pp.494-498 (2001).	L.				
	C11	Fawell et al., Proc. Natl. Acad. Sci. (USA), Vol. 91, pp.664-668 (1994).					
	C12	Ferkol et al., FASEB J., Vol. 7, pp.1081-1091 (1993).					
	C13	Fingel et al., "The Pharmacological Basis of Therapeutics," Ch. 1, pp.1 (1975).					
	C14	Fire et al., Nature, Vol. 391, pp.806-811 (1998).					

Examiner Signature	/Stephen Kapushoc/	•	Date Considered	01/12/2010
22224				(h-1-1-100)-00-(h-1-1)

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/567,630-Conf. #2853	
11	NFORMATION	V DIS	SCLOSURE	Filing Date	February 8, 2006	
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Kari Alitalo	
				Art Unit	Notiver assigned 1634	
	(Use as many sh	eets as	necessary)	Examiner Name	Kapushoc	
Sheet	2	of	2	Attorney Docket Number	28113/39467A	

	C15	Fujimori et al., J. Biol. Chem., Vol. 278, pp.6018-6026 (2003).	
	C16	Giles et al., Biochem. Biophys. Acta., Vol. 1653, pp.1-24 (2003).	
	C17	Gupta et al., Nat. Rev. Cancer, Vol. 1, pp.11-21 (2001).	
	C18	Hong et al., Dev. Dyn., Vol. 225, pp.351-357 (2002).	
	C19	Hutvagner et al., Science, Vol. 297, pp.2056-2060 (2002).	
	C20	Jensen et al., Nat. Genet., Vol. 24, pp.36-44 (2000).	
	C21	Jordan et al., J. Clin. Invest., Vol. 104, pp.1061-1069 (1999).	
	C22	Joutel et al., Nature, Vol. 383, pp.707-710 (1996).	
•	C23	Kaneda et al., Science, Vol. 243, pp.375-378 (1989).	
	C24	Kato et al., J. Biol. Chem., Vol. 266, pp.3361-3364 (1991).	
	C25	Kawasaki et al., Nature, Vol. 423, pp.838-842 (2003).	
	C26	Koizumi et al., Nucleic Acid Res., Vol. 17, pp.7059-7071 (1989).	
	C27	Kurreck et al., Nucleic Acids Res., Vol. 30, pp.1911-1918 (2002).	
	C28	Ladner et al., Cancer Research, Vol. 60, pp.3493-3503 (2000).	
	C29	Lee et al., Natl. Biotechnol., Vol. 20, pp.500-505 (2002).	
	C30	Li et al., Nature Genet., Vol. 16, pp.243-251 (1997).	
	C31	Lima et al., J. Biol. Chem., Vol. 272, pp.626-638 (1997).	
	C32	Long et al., FASEB J., Vol. 7, pp.25-30 (1993).	
	C33	Martinez et al., Cell, Vol. 110, pp.563-574 (2002).	
	C34	Morrison et al., Proc. Natl. Acad. Sci. (USA), Vol. 81, pp.6851-6855 (1984).	
	C35	Nagahara et al., Nature Medicine, Vol. 4, pp.1449-1452 (1998).	
<u> </u>	C36	Nicolau et al., Methods Enzymol., Vol. 149, pp.157-176 (1987).	
	C37	Ojwang et al., Proc. Natl. Acad. Sci. (USA), Vol. 89, pp.10802-10806 (1992).	
	C38	Palmer et al., J. Cell Biol., Vol. 154, pp.369-387 (2001).	
<b> </b>	C39	Perales et al., Proc. Natl. Acad. Sci. (USA), Vol. 91, pp.4086-4090 (1994).	
	C40	Perrotta et al., Biochem, Vol. 31, pp.16-17 (1992).	
	C41	Petrova et al., Embo J., Vol. 21, pp.4593-4599 (2002).	
<b></b>	C42	Quaroni et al., Am. J. Physiol. Cell. Physiol., Vol. 279, pp.C1045-1057 (2000).	
	C43	Schwarze et al., Science, Vol. 285, pp.1569-1572 (1999).	
	C44	Sosa-Pineda et al., Nat. Genet., Vol. 25, pp.254-255 (2000).	
	C45	Symons, Ann. Rev. Biochem., Vol. 61, pp.641 (1992).	
	C46	Takeda et al., Nature, Vol. 314, pp.452-454 (1985).	
	C47	Tomita et al., Cancer Res., Vol. 52, pp.6840-6847 (1992).	
ļ —	C48	Tuschl, Nat. Biotechnol., Vol. 20, pp.446-448 (2002).	
	C49	Usman et al., Current Opin. Struct. Biol., Vol. 6, pp.527-533 (1996).	
	C50	van de Wetering et al., Cell, Vol. 111, pp.241-250 (2002).	
	C51	White et al., Cancer Res., Vol. 62, pp.1669-1675 (2002).	
	C52	Wigle et al., Cell, Vol. 98, pp.769-778 (1999).	
	C53	Wigle et al., Nat. Genet., Vol. 21, pp.318-33 (1999).	
	C54	Yamada et al., Neurol Res., Vol. 24, pp.244-248 (2002).	
	C55	Yang et al., Cancer Res., Vol. 61, pp.565-569 (2001).	
	C56	Yang et al., <i>Science</i> , Vol. 294, pp.2155-2158 (2001).	
	C57	Yu et al., Proc. Natl. Acad. Sci. (USA), Vol. 99, pp.6047-6052 (2002).	
	C58	Zeng et al., <i>Mol. Cell</i> , Vol. 9, pp.1327-1333 (2002).	

Examiner	(0: 1 1/ 1 1	Date	01/12/2010
Signature	/Stephen Kapushoc/	Considered	01/12/2010
020014			